HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

REACH Information Requirements Have Changed; ECHA Preparing Guidance

Executive Summary

The European Chemicals Agency is targeting the back half of 2022 for guidance on revised information requirements for substances registered under REACH, following a European Commission regulation published in March.

You may also be interested in...



ECHA Reviewing Discounted REACH Fees To Ensure SMEs Truly Qualify

The European Chemicals Agency will be asking companies that benefited from reduced fees on REACH registrations during the 2013-2015 period to provide documentation verifying their SME status. Registrants need to be checking REACH-IT regularly and potentially taking proactive measures to avoid penalties.

Senate HELP Floats Draft For US Cosmetics Reform; Top Trade Groups Hustle To Respond

Bundled within the draft FDA Safety and Landmark Enhancements Act are federal cosmetics reform provisions that would require facility registration and product listings with the US FDA, adverse event reporting and good manufacturing practices, while empowering the agency to order product recalls, access company records, and suspend dangerous operations.

Inter Parfums’s Q1 Sales Up 26% In ‘Robust Environment’ For Fragrance

The New York-based manufacturer of prestige perfumes and cosmetics is “extremely optimistic” about fiscal 2022 and the years ahead, recording net sales growth of 26% in the first quarter, led by major brand innovations, and projecting an 11% increase for the full year.

Topics

UsernamePublicRestriction

Register

RS152510

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel